<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445081</url>
  </required_header>
  <id_info>
    <org_study_id>TUD_PROVE_001</org_study_id>
    <secondary_id>EudraCT-Nr:2006-003667-31</secondary_id>
    <nct_id>NCT00445081</nct_id>
  </id_info>
  <brief_title>Prednisolone vs. Ciclosporine in Severe Atopic Eczema</brief_title>
  <acronym>PROVE</acronym>
  <official_title>Prednisolone vs. Ciclosporine in Severe Atopic Eczema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universit채t Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universit채t Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the comparative efficacy of Ciclosporine A and Prednisolone in adult patients
      with severe atopic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>stable remission in both treatment groups</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate in both treatment groups</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse rate in both treatment groups</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean change in objective SCORAD in both treatment groups</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean change in HRQL (DLQI) in both treatment groups</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in disease symptoms (POEM)in both treatment groups</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of both treatments</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability and Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in presenteeism in both treatment groups</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporine A</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and female patients age &gt;= 18 and &lt; 55

          -  weight between 50 and 100 kg

          -  confirmed diagnosis of AE (UK working party criteria)

          -  objective SCORAD &gt; 40

          -  DLQI &gt; 10

          -  resistancy against topical treatment options including steroids and
             calcineurin-inhibitors

        Exclusion Criteria:

          -  participation to another clinical trial within the last 4 weeks before baseline

          -  pregnant or breastfeeding

          -  women of childbearing potential without adequate contraception

          -  allergy against prednisolone or Ciclosporine A

          -  acute bacterial or viral infection

          -  malignant tumor in personal history

          -  diabetes mellitus

          -  arterial hypertension

          -  Glaucoma

          -  peptic ulcer

          -  severe osteoporosis

          -  tuberculosis in personal history

          -  colitis ulcerosa

          -  diverticulitis

          -  concurrent treatment with chloroquin, Mefloquin, Statins, Warafin

          -  Creatinin Clearance &lt; 60 ml /min

          -  UV treatment within 8 weeks before inclusion

          -  ongoing systemic immunosuppressive treatment

          -  planned vaccination within 8 weeks before study entry, during study and 2 weeks after
             end of study

          -  Poliomyelitis

          -  Lymphadenitis after BCG vaccination

          -  Hyperuricaemia

          -  chronic liver disease

          -  Xeroderma pigmentosum, Cockaye-Syndrome, Bloom Syndrome

          -  Psychiatric co-morbidity

          -  drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jochen M Schmitt, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dpt. of Dermatology, TU Dresden, Fetscherstr 74, D-01307 Dresden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Dermatology and Venerology Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Dermatology, Medical Faculty, TU Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dpt. of Dermatology, Medical Faculty Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dpt. of Dermatology, University Hospital M체nster</name>
      <address>
        <city>M체nster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2007</study_first_posted>
  <last_update_submitted>October 28, 2010</last_update_submitted>
  <last_update_submitted_qc>October 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jochen Schmitt, MD, MPH</name_title>
    <organization>Technical University Dresden</organization>
  </responsible_party>
  <keyword>atopic dermatitis</keyword>
  <keyword>prednisolone</keyword>
  <keyword>ciclosporine</keyword>
  <keyword>SCORAD</keyword>
  <keyword>DLQI</keyword>
  <keyword>QALY</keyword>
  <keyword>WLQ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

